Charles River Laboratories International (CRL) Expected to Announce Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) is anticipated to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $2.74 per share and revenue of $977.1980 million for the quarter. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company posted $2.34 earnings per share. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Trading Down 0.0%

CRL stock opened at $232.49 on Monday. The business has a fifty day moving average of $206.60 and a 200-day moving average of $187.92. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market cap of $11.20 billion, a P/E ratio of -61.83, a PEG ratio of 2.59 and a beta of 1.40. Charles River Laboratories International has a twelve month low of $144.26 and a twelve month high of $242.73.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Invesco Ltd. increased its position in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the period. State Street Corp increased its holdings in shares of Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after purchasing an additional 40,535 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Charles River Laboratories International by 27.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock valued at $287,703,000 after buying an additional 311,319 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Charles River Laboratories International by 13.4% in the third quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after buying an additional 137,335 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Charles River Laboratories International by 33.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 769,437 shares of the medical research company’s stock valued at $120,386,000 after buying an additional 190,828 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CRL. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Morgan Stanley upped their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Finally, Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $220.75.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.